Mizoribine oral pulse therapy for a patient with severe lupus nephritis

Pediatrics International

Volumn 45, Issue 4, 2003, Pages 488-490

  Tanaka, Hiroshi ^a   Suzuki, Koichi ^a   Nakahata, Tohru ^a   Sato, Tomohiko ^a   Ito, Etsuro ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Anti dsDNA antibody; Lupus nephritis; Mizoribine; Oral pulse therapy; Systemic lupus erythematosus

Indexed keywords

METHYLPREDNISOLONE; MIZORIBINE; PREDNISOLONE;

ARTICLE; CASE REPORT; DISEASE SEVERITY; DRUG EFFICACY; DRUG PULSE THERAPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HERPES ZOSTER; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; JAPAN; KIDNEY BIOPSY; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SCHOOL CHILD; SJOEGREN SYNDROME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; CHILD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; RIBONUCLEOSIDES; SEVERITY OF ILLNESS INDEX;

EID: 0141519632     PISSN: 13288067     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-200X.2003.01749.x     Document Type: Article

References (9)

1. Yokota S. Mizoribine: Mode of action and effects in clinical use. Pediatr. Int. 2002; 44: 196-8.
2. Hamasaki T, Mori M, Kinoshita Y, Saeki T, Sakano T. Mizoribine in steroid-dependent nephrotic syndrome of childhood. Pediatr. Nephrol. 1997; 11: 625-7.
3. Yoshioka K, Ohashi Y, Sakai T et al. A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney Int. 2000; 58: 317-24.
4. Aihara Y, Miyamae T, Ito S et al. Mizoribine as an effective combined maintenance therapy with prednisolone in childhood-onset systemic lupus erythematosus. Pediatr. Int. 2002; 44: 199-204.
5. Yumura W, Uchida K, Kawashima A et al. Evaluation of Plasma Concentration of Mizoribine as an Immunosuppressive Agent in Lupus Nephritis Patients. Jin to Toseki (Kidney and Dial Tokyo) 1999; 47: 705-8 [in Japanese].
6. Fukunishi T, Takahashi S, Hashinaka Y et al. Bredinin concentration in blood and immunosuppressive effect. Ishyoku (Jpn J. Transplant) 1982; 17 (Suppl.): 750-2 [in Japanese].
7. Sonda K, Takahashi K, Tanabe K et al. Clinical pharmacokinetic study of mizoribine in renal transplantation patients. Transplant Proc. 1996; 28: 3643-8.
8. Austin HA, Muenz LR, Joyce KM, Antonnovych TT, Balow JE. Diffuse proliferative lupus nephritis: Identification of specific pathologic features affecting renal outcome. Kidney Int. 1984; 25: 689-95.
9. Tanaka H, Tateyama T, Waga S. Methylprednisolone pulse therapy in Japanese children with severe lupus nephritis. Pediatr. Nephrol. 2001; 16: 817-9.